ChemicalBook > Product Catalog >API >Antineoplastic agents >Hormonal antineoplastic drugs >Letrozole

Letrozole

Letrozole Suppliers list
Company Name: Jinan Aery Pharmaceutical Co,.Ltd
Tel: 0531-81263406
Email: sales@aerpharm.com
Products Intro: Product Name:Letrozole
CAS:112809-51-5
Purity:98.5 Package:10g;1USD|100g;1USD|500g;3USD|1KG;10USD|10KG;20USD
Company Name: Beijing Yibai Biotechnology Co., Ltd
Tel: 0086-182-6772-3597
Email: sales04@yibaibiotech.com
Products Intro: Product Name:Letrozole
CAS:112809-51-5
Purity:99% Package:1g;0USD|10g;0USD|100g;0USD|1KG;0USD
Company Name: Hebei Bonster Technology Co.,Limited
Tel: +86-13315996897
Email: Wendy@bsterltd.com
Products Intro: Product Name:Letrozole
CAS:112809-51-5
Purity:0.99 Package:1g;10g;50g;100g;1kg;5KG;25kg
Company Name: WUHAN CIRCLE POWDER TECHNOLOGY CO.,LTD
Tel: 027-81302090
Email: 2851686515@qq.com
Products Intro: Product Name:Letrozole
CAS:112809-51-5
Purity:99%
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: 0371-55170693
Email: info@tianfuchem.com
Products Intro: Product Name:Letrozole
CAS:112809-51-5
Purity:0.99 Package:25KG,5KG;1KG;500G

Lastest Price from Letrozole manufacturers

  • Letrozole
  • US $0.00 / KG
  • 2020-10-24
  • CAS:
  • Min. Order: 100g
  • Purity: 98%+
  • Supply Ability: 100kg
  • Letrozole
  • US $1024.00 / KG
  • 2020-10-24
  • CAS:112809-51-5
  • Min. Order: 100g
  • Purity: 98%+
  • Supply Ability: 100kg
  • Letrozole
  • US $850.00 / 公斤
  • 2020-09-22
  • CAS:112809-51-5
  • Min. Order: 1g
  • Purity: 99%
  • Supply Ability: 5000kg

Related articles

  • What is Letrozole?
  • Letrozole (Femara?) is a nonsteroidal, third-generation aromatase inhibitor administered orally once daily, which has shown ef....
  • Feb 10,2020
Letrozole Basic information
Indications and uses Pharmacokinetics Side effects
Product Name:Letrozole
Synonyms:LetrozoleUsp28;Letrozole99%;CGS-20267, Femara;LETRAZOLE;letrozolex;Lelrozol;1-[BIS(4-CYANOPHENYL)METHYL]-1,2,4-TRIAZOLE;4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile
CAS:112809-51-5
MF:C17H11N5
MW:285.30274
EINECS:675-034-8
Product Categories:Anti-cancer&immunity;Aromatics;Heterocycles;APIs;Antibiotics;ELOXATIN;Pharmaceuticals;API's;Inhibitors;Intermediates & Fine Chemicals;Active Pharmaceutical Ingredients;All Inhibitors;anti-neoplastic;Pharmaceutical material and intermeidates;Anti-Cancer;Letrozole;Antineoplastic
Mol File:112809-51-5.mol
Letrozole Structure
Letrozole Chemical Properties
Melting point 181-183°C
Boiling point 563.5±60.0 °C(Predicted)
density 1.21±0.1 g/cm3(Predicted)
storage temp. -20°C Freezer
solubility DMSO: >50mg/mL
form White powder
pka1.52±0.11(Predicted)
color white to off-white
Merck 14,5450
InChIKeyHPJKCIUCZWXJDR-UHFFFAOYSA-N
CAS DataBase Reference112809-51-5(CAS DataBase Reference)
Safety Information
Hazard Codes Xi
Risk Statements 36/37/38
Safety Statements 26-36
WGK Germany 3
RTECS DI4957000
HS Code 2933997500
Hazardous Substances Data112809-51-5(Hazardous Substances Data)
MSDS Information
Letrozole Usage And Synthesis
Indications and usesLetrozole is part of a new generation of highly selective aromatase inhibitors and is an artificially synthesized benzotriazole derivative. Letrozole inhibits aromatase to lower estrogen levels, thus preventing estrogen from stimulating tumor growth. Its in vivo activity is 150-250 times stronger than that of first generation aromatase inhibitor Amarante. As it is highly selective, it will not impact glucocorticoid, mineralocorticoid and thyroid functions; even at high dosages, it will not have any inhibiting effects on adrenal corticosteroid secretion, giving it a high treatment index. Letrozole has no latent toxicity towards any bodily systems and target organs, has no mutagenicity and carcinogenic effects, has minimal toxic side effects, is well-tolerated, and has stronger anticancer effects than other aromatase inhibitors and antiestrogen drugs. Letrozole is suitable for advanced breast cancer postmenopausal patients who have not responded to estrogen-suppressing treatment and for early breast cancer treatment. It is used to treat postmenopausal patients with advanced breast cancer and serves as a second-line treatment to follow unsuccessful antiestrogen treatment. Compared to the current standard Tamoxifen treatment, Letrozole can better prevent the risk of breast cancer recurrence.
Pharmacokinetics

Absorption of oral letrozole is rapid and complete and steady state is achieved in 2–6 weeks with administration of letrozole 2.5mg once daily. The major route of elimination of letrozole is via metabolism to a pharmacologically inactive carbinol metabolite. The cytochrome P450 (CYP) 3A4 and CYP2A6 isozymes metabolize letrozole to a pharmacologically inactive carbinol metabolite. Renal excretion of a glucuronide conjugate of the carbinol metabolite of letrozole represents the major route of drug clearance.

Side effectsRandomized grouping studies have shown that daily oral ingestion of 2.5mg Letrozole leads to a 33% rate of drug-related negative reactions, a percentage much lower than AG group’s 46%. Negative reactions to Letrozole are mostly mild or moderate, consisting mostly of nausea (2-9%), headache (0-7%), bone pain (4-10%), hot flashes (0-9%) and weight gain (2-8%). Other uncommon side effects include constipation, diarrhea, itching, rash, joint pain, chest pain, abdominal pain, fatigue, insomnia, dizziness, edema, high blood pressure, arrhythmia, thrombosis, dyspnea, vaginal bleeding, etc.
DescriptionLetrozole (trade name: Femara) is an orally active nonsteroidal aromatase inhibitor. As a competitive inhibitor of the aromatase, Letrozole inhibits the conversion of androgens to estrogen (estrogen stimulates breast tissues and breast cancer reoccurrence) and gonadal steroidogenesis. It can be used for the treatment of breast cancer that is hormonally-responsive or has an unknown receptor status in postmenopausal women. Besides this, Letrozole also has some off-label use such as ovarian stimulation, pretreatment of termination of pregnancy, treatment of gynecomastia, treatment of endometriosis, and promoting spermatogenesis for male patients of nonobstructive azoospermia.
Chemical Propertieswhite to light yellow crystal
OriginatorNovartis (Switzerland)
UsesA nonsteroidal aromatase inhibitor structurally related to Fadrozole. Antineoplastic
Manufacturing ProcessFrom 4-bromomethylbenzonitrile and 1H-[1,2,4]triazole was obtained 4- [1,2,4]triazol-1-ylmethylbenzonitrile. Treatment of that with strong base (tertBuOK) results in formation of the anion by removal of the relatively acidic benzyl proton. This anion was condensed with p-fluorobenzinitrile to give benzhydryl tetrazole (Letrozole)
Brand nameFemara (Novar tis).
Therapeutic FunctionAntineoplastic
General DescriptionLetrozole, 4,4'-(1H-1,2,4-triazol-1-ylmethylene)dibenzonitrile (Femara), is used for most of thesame indications as anastrozole. It reduces concentrations ofestrogens by 75% to 95%, with maximal suppressionachieved within 2 to 3 days. Letrozole is specific for aromataseinhibition, with no additional effects on adrenal corticoidbiosynthesis. CYPs 3A4 and 2A6 are involved in themetabolism of letrozole to the major carbinol metabolite,which is inactive. The loss of the triazole ring, which is involvedin coordination of the heme iron, would explain theloss of activity. Letrozole strongly inhibits CYP2A6 invitro, with moderate inhibition of CYP2C19. The effect ofthis in vitro inhibition on the pharmacokinetics of coadministereddrugs is unknown. Tamoxifen reduces the levels ofletrozole significantly if they are used together, so combinationtreatment with these agents is not recommended.
Mechanism of actionInhibition of arom atase by letrazole is competitive and highly specific , with no effect on enzymes that are responsible for the production of glucocorticosteroids and mineralocorticosteroids. This agent is significantly more effective than tamoxifen in treating horm one-dependent cancer.
Clinical UseFemara was launched in France and the UK for second-line treatment of advanced breast cancer. Letrazole can be synthesized in two steps from 4- bromomethyl-benzonitrile with 1,2,4-triazole and is a third generation aromatase inhibitor. It is a highly specific inhibitor of P450arom which prevents the conversion of androstenedione to estrone. The reduction of plasma estrogen was immediate and long lasting. This is accomplished with no inhibition of other steroid biosynthesis making it the most selective aromatase inhibitor tested. Letrazole has remarkable antitumor activity, is well tolerated and has no toxic side effects. It is 10,000 times more potent than aminoglutethimide, in vivo, the first well established aromatase inhibitor.
Referenceshttps://www.drugbank.ca/drugs/DB01006
https://en.wikipedia.org/wiki/Letrozole
Tag:Letrozole(112809-51-5) Related Product Information
[1-Hydroxy-3-(methylpentylamino)-propylidene]bisphosphonic acid sodium salt Irinotecan hydrochloride trihydrate 4,4''-DICYANOBENZOPHENONE(INTERMEDIATE OF LETROZOLE ) 4-[α-(4-Cyanophenyl)-hydroxymethyl]-benzonitrile ( For Letrozole ) 5-Methyl-1,3-benzenediacetonitrile 4-BENZYLBENZONITRILE 4,4'-(1-METHYLENE) BIS-BENZONITRILE 1-BENZHYDRYL-1,2,4-TRIAZOLE (S)-1-(4-CYANOPHENYL)ETHANAMINE 1,1-bis(4-methylphenyl)methanamine (R)-1-(4-CYANOPHENYL)ETHANAMINE 4-((1H-1,2,4-triazol-1-yl)methyl)benzonitrile (intermediate of letrozole),INTERMEDIATE OF LETROZOLE,4-[1-(1,2,4-triazolyl)-methyl]-benzonitrile ( For Letrozole ) 4-Cyanobenzylamine Letrozole 5-Methyl-1H-benzotriazole Chlorodimethylphenylsilane Tolyltriazole 1,2,4-Triazole